Proteomics International Laboratories Ltd (PIQ.AX) OxiDx Platform Technology Secures Patent in Japan
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its subsidiary OxiDx Pty Ltd (OxiDx; the Company) has been granted a patent in Japan for its platform technology to measure oxidative stress. The patent marks the first of a new family of patents for OxiDx's next generation diagnostics technology and is another illustration of Proteomics International's specialist platform technologies.
- First of a new family of patents for the OxiDx technology has been granted in Japan
- OxiDx's next generation diagnostics technology offers a comprehensive solution for monitoring oxidative stress levels using a simple fingerprick blood test
- Oxidative stress has been implicated in many chronic diseases - target applications include chronic fatigue, muscular dystrophy, high-performance athletes and the horse racing industry
Oxidative stress is implicated in over 70 health conditions with levels often reflective of a person's health and fitness.
Proteomics International Managing Director Dr Richard Lipscombe said the patent was a significant milestone towards commercialising OxiDx's ground breaking technology across a range of key markets. "Securing this IP protection in a major jurisdiction like Japan signifies a recognition of the uniqueness of the OxiDx intellectual property and bodes well for the OxiDx's pending patent applications for this technology in other jurisdictions."
Measuring oxidative stress has broad application across multiple markets including as a complementary diagnostic (CDx) test for assessing treatment efficacy and precision medicine by enabling personalised dosing in clinical trials, or as an athletic monitoring tool for competition preparedness and to reduce injuries in the Professional Sports and Horse Racing Industries.
Executive chair of OxiDx, Ian Brown said our technology is already well-proven with over 20 academic publications on its use including in diseases like Duchenne Muscular Dystrophy. "We are now embarking on field trials to demonstrate further applicability, initially in high-performance athletes and the horse racing industry. This patent helps ensure OxiDx's technology is secured for many years to come, as we look forward to expanding into multiple markets and revolutionising the way oxidative stress is monitored and managed."
OxiDx uses next generation diagnostics technology, moving beyond measuring protein concentrations to detect subtle changes in protein structures - 'decorations' that sit on the surface of a protein and are known as post-translational modifications. The Company's platform technology measures systemic oxidative stress in a fingerpick blood sample by using a sensitive ratio-metric method to detect protein biomarkers in the blood. Samples can be collected in the home, clinic or on the field with high specificity to provide a comprehensive solution for monitoring oxidative stress levels [ASX 22 August 2023].
The Japanese patent (No. 7325436) entitled "Methods for measuring relative oxidation levels of a protein" is valid until March 2039, and is part of a family of new patent applications in all major jurisdictions (see PIQ Annual Report 2023). These new patents, if granted, will greatly extend the lifespan and regional coverage of the Company's existing intellectual property portfolio.
About OxiDx Pty Ltd
OxiDx (Perth, Western Australia) is an independent spin-off by Proteomics International and the University of Western Australia (ASX 29 August 2022), dedicated to developing innovative products for measuring oxidative stress, a condition which has been implicated in multiple health conditions.
OxiDx's patented sentinel platform technology offers high specificity in assessing systemic oxidative stress using a simple fingerpick blood sample. Target applications of the technology currently include high-performance athletes, the horse racing industry and as a complementary diagnostic (CDx) test to support clinical trials.
Dr Richard Lipscombe Managing Director Proteomics International Laboratories Ltd T: +61 8 9389 1992 E: enquiries@proteomicsinternational.com Dirk van Dissel Investor Relations & Corporate Advisor Candour Advisory T: +61 408 326 367 E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Euroz Hartleys T: +61 8 9488 1400 E: kmoss@eurozhartleys.com
News Provided by ABN Newswire
